InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
- PharmAust Receives $708k R&D Tax Incentive Refund 19 Apr 2022 8:22AM $0.091 $0.230 risen by 152.75%
- PAA appoints trial manager & receives $200k from FightMND 8 Apr 2022 8:57AM $0.089 $0.230 risen by 158.43%
- Notification of cessation of securities - PAA 31 Mar 2022 7:05PM $0.095 $0.230 risen by 142.11%
- MPL manufactured and tableting commenced 15 Mar 2022 8:20AM $0.094 $0.230 risen by 144.68%
- Preliminary MPL antiviral leukaemia preclinical WEHI results 23 Feb 2022 11:13AM $0.095 $0.230 risen by 143.39%
- Key Appointment to Progress MPL COVID-19 Clinical Trial 21 Feb 2022 8:04AM $0.100 $0.230 risen by 130%
- Appendix 4D & Half Year Report 18 Feb 2022 5:53PM $0.100 $0.230 risen by 130%
- Epichem Confirms Effectiveness of OHD E-Waste Project 16 Feb 2022 8:10AM $0.095 $0.230 risen by 142.11%
- Resignation of Epichem CEO 3 Feb 2022 11:36AM $0.098 $0.230 risen by 134.69%
- Update on Manufacture of MPL & Tablets for Clinical Trials 2 Feb 2022 9:25AM $0.099 $0.230 risen by 132.32%
- Appendix 4C and Quarterly Update 31 Jan 2022 10:00AM $0.099 $0.230 risen by 132.32%
- Epichem Awarded Contract Extension from DNDi 15 Dec 2021 9:11AM $0.090 $0.230 risen by 155.56%
- Shareholder Update - Progress and Strategy 13 Dec 2021 8:49AM $0.097 $0.230 risen by 137.11%
- Demonstration batch of smaller size MPL tablets completed 1 Dec 2021 8:15AM $0.098 $0.230 risen by 134.69%
- MND & COVID-19 Phase 1 Clinical Trials On-Track 17 Nov 2021 8:22AM $0.110 $0.230 risen by 109.09%
- Cleansing Notice 16 Nov 2021 5:53PM $0.110 $0.230 risen by 109.09%
- Application for quotation of securities - PAA 16 Nov 2021 5:48PM $0.110 $0.230 risen by 109.09%
- Canine phase 2b cancer trial expands to New Zealand 15 Nov 2021 8:37AM $0.120 $0.230 risen by 91.67%
- JobKeeper Payment Notification 12 Nov 2021 2:22PM $0.118 $0.230 risen by 95.74%
- Change of Director's Interest Notice x 4 9 Nov 2021 1:48PM $0.105 $0.230 risen by 119.05%
- PAAO Top 20 Holders & Distribution Schedule 9 Nov 2021 1:36PM $0.105 $0.230 risen by 119.05%
- Application for quotation of securities - PAA 9 Nov 2021 11:02AM $0.110 $0.230 risen by 109.09%
- Closure of Entitlement Offer 5 Nov 2021 2:45PM $0.105 $0.230 risen by 119.05%
- Appendix 4C and Quarterly Update 29 Oct 2021 11:32AM $0.100 $0.230 risen by 130%
- Results of Annual General Meeting 22 Oct 2021 8:15AM $0.096 $0.230 risen by 139.58%

251 - 275 of 796 results

Page 11 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.